$ACRV insider trading
Over the last 12 months, Acrivon Therapeutics insiders reported 3 buys totaling $114K and 11 sales totaling $41K across SEC Form 4 filings.
- Bought · 12m
- $114K 3 events
- Sold · 12m
- $41K 11 events
- Events · 12m
- 14 Form 4 filings, grouped
- Insiders · 12m
- 6 distinct reporters
- 10b5-1 share
- 0% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Oct 22, 2026 | Miller MaryChief Legal Officer · O | ▼ Sale | 513 | $1.84 | $944 | -0.6% | — |
| Oct 5, 2026 | Miller MaryChief Legal Officer · O | ▼ Sale | 294 | $1.99 | $585 | -0.4% | — |
| Aug 25, 2026 | Blume-Jensen PeterPresident and CEO · O·D | ▼ Sale | 14,036 | $2.21 | $31K | -0.6% | — |
| Aug 18, 2026 | Peterson KatharineChief Accounting Officer · O | ▼ Sale | 101 | $2.01 | $203 | -0.6% | — |
| Aug 18, 2026 | Miller MaryChief Legal Officer · O | ▼ Sale | 185 | $2.01 | $372 | -0.2% | — |
| Aug 18, 2026 | Gamelin ErickChief Development Officer · O | ▼ Sale | 400 | $2.01 | $804 | -0.8% | — |
| Aug 18, 2026 | Devroe EricChief Operating Officer · O | ▼ Sale | 604 | $2.01 | $1K | -0.4% | — |
| Aug 18, 2026 | Blume-Jensen PeterPresident and CEO · O·D | ▼ Sale | 484 | $2.01 | $973 | -0.1% | indirect |
| Aug 18, 2026 | Blume-Jensen PeterPresident and CEO · O·D | ▼ Sale | 1,229 | $2.01 | $2K | -0.1% | — |
| Aug 4, 2026 | Levy Adam D.Chief Financial Officer · O | ▼ Sale | 1,142 | $1.57 | $2K | -1.7% | — |
| Jul 21, 2026 | Miller MaryChief Legal Officer · O | ▼ Sale | 573 | $1.76 | $1K | -0.7% | — |
| Jan 14, 2026 | Blume-Jensen PeterPresident and CEO · O·D | ▲ Buy | 49,000 | $1.68 | $82K | +2.4% | — |
| Jan 14, 2026 | Levy Adam D.Chief Financial Officer · O | ▲ Buy | 8,832 | $1.7 | $15K | +72.7% | — |
| Jan 13, 2026 | Devroe EricChief Operating Officer · O | ▲ Buy | 10,000 | $1.72 | $17K | +15.3% | — |
Every $ACRV filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Acrivon Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ACRV feed.